epirubicin has been researched along with Neutropenia in 144 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.39) | 18.7374 |
| 1990's | 39 (27.08) | 18.2507 |
| 2000's | 62 (43.06) | 29.6817 |
| 2010's | 37 (25.69) | 24.3611 |
| 2020's | 4 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Ogino, M; Sakoda, Y; Suzuki, H; Tsuchiya, K | 1 |
| Ahari, A; Chawla, SP; Chua, V; Krkyan, N; Moradkhani, A; Osada, A; Riedel, RF | 1 |
| Matsubara, H; Nakamura, T | 1 |
| Asano, Y; Futamura, M; Hosono, Y; Ikawa, A; Ishihara, K; Katagiri, Y; Kawaguchi, Y; Kawajiri, M; Kitazawa, M; Kumazawa, I; Kuno, M; Matsuhasih, N; Mori, R; Morikawa, A; Mushika, Y; Nagao, Y; Nakada, T; Nakakami, A; Niwa, Y; Ogiso, A; Shimokawa, T; Takeuchi, M; Tokumaru, Y | 1 |
| Goodwin, A; O'Connell, DL; Wilcken, N; Willson, ML; Zaheed, M | 1 |
| Funakoshi, T; Hirai, I; Ishii, M; Kawakami, Y; Nakamura, Y; Tanese, K | 1 |
| Baines, S; Elliott, J | 1 |
| Blohmer, JU; Costa, SD; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Höß, C; Huober, J; Jackisch, C; Khandan, F; Kittel, K; Krabisch, P; Kümmel, S; Loibl, S; Mau, C; Minckwitz, Gv; Nekljudova, V; Rezai, M; Schwedler, K; Tesch, H; Untch, M | 1 |
| Eatock, MM; Gallagher, R; James, CR; Law, D; Millar, J; Morris, M; Napier, E; Purcell, C; Turkington, RC; Wilson, RH | 1 |
| Biagioni, C; Biganzoli, L; Cavaciocchi, D; Di Leo, A; Pestrin, M; Sanna, G; Turner, N; Zafarana, E | 1 |
| Fukuma, E; Higaki, K; Masuda, N; Mizutani, M; Ohno, S; Osaki, A; Saeki, T; Sagara, Y; Sato, K; Suzuki, M; Takano, T; Tokuda, Y | 1 |
| Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Malamos, N; Mavroudis, D; Papakotoulas, P; Politaki, E; Polyzos, A; Tryfonidis, K; Xenidis, N | 1 |
| Ando, M; Aogi, K; Fujiwara, Y; Hamano, T; Inoue, K; Iwata, H; Kuroi, K; Masuda, N; Ohono, S; Shimizu, S; Sukigara, T; Yamamoto, N; Yamauchi, H | 1 |
| Friberg, LE; Karlsson, MO; Lindman, H; Quartino, AL | 1 |
| Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M | 1 |
| Fan, T; Fan, Z; Li, J; Ouyang, T; Wang, T; Wang, X; Xie, Y | 1 |
| Hao, X; Li, C; Su, W; Zhang, J; Zhang, S | 1 |
| Cao, J; Guo, W; Huang, M; Ji, D; Li, J; Liu, R; Peng, W; Sun, S; Wang, C; Yin, J; Zhao, X; Zhu, X | 1 |
| Bi, J; Cao, B; Chen, L; Dai, H; Deng, Y; Hu, J; Jia, L; Jiang, H; Li, W; Meng, C; Nan, K; Shen, K; Shen, P; Shi, J; Song, Y; Sun, Q; Sun, Y; Tang, L; Tian, F; Tong, Z; Wang, S; Wu, G; Wu, Q; Wu, Y; Xie, X; Xu, B; Yu, J; Yuan, Z; Yue, S; Zhang, B; Zhang, Q; Zhang, Y; Zhuang, W | 1 |
| Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E | 1 |
| Fuchikami, H; Iwai, M; Mizuno, Y; Sato, K; Takeda, N | 1 |
| Fujiwara, D; Kimura, K; Mashimo, K; Nishida, S; Noda, A; Sakaguchi, K; Takeda, T; Taki, K; Tsubaki, M; Yoshibayashi, H | 1 |
| Davies, A; Gandara, D; Huynh, M; Johl, J; Lara, P; Lau, D; Tanaka, M | 1 |
| Freeman, S; Jenkins, P | 1 |
| Ding, G; Fu, Q; Ren, H; Su, FX; Wang, N; Wang, YJ; Wu, Q; Yang, JQ; Ye, ZB; Zhang, J; Zhou, LZ | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Agarwal, R; Ashley, S; Chua, S; Johnston, S; Jones, RL; O'Brien, M; Smith, IE; Walsh, G | 1 |
| Gennatas, K; Gennatas, S; Michalaki, V | 1 |
| Barrett-Lee, P; Bartlett, JM; Bliss, JM; Bloomfield, D; Cameron, D; Canney, P; Coleman, R; Dowsett, M; Earl, H; Ellis, I; Ellis, P; Hall, E; Hopwood, P; Johnson, L; Johnston, S; O'Reilly, S; Peckitt, C; Poole, C; Smith, I; Twelves, C; Verrill, M; Wardley, A; Yarnold, J | 1 |
| Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G | 1 |
| Addeo, R; Capasso, E; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Guarrasi, R; Montella, L | 1 |
| Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD | 1 |
| Anami, S; Fujii, C; Kitada, N; Kondoh, M; Minegaki, T; Morita, S; Nishino, M; Takara, K; Watari, M; Yasuda, J | 1 |
| Ardavanis, A; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kentepozidis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Ziras, N | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K | 1 |
| Conrad, B; Forstbauer, H; Koehne, CH; Kremers, S; Linder, M; Loibl, S; Moebus, V; Mueller, V; Nekljudova, V; von Minckwitz, G | 1 |
| Al Zaman, A; Fraser, J; Steele, N; Yule, A | 1 |
| Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Kim, SJ; Maruyama, N; Nakayama, T; Noguchi, S; Okishiro, M; Shimazu, K; Shimomura, A; Tamaki, Y; Tsunashima, R | 1 |
| Anderson, JR; Dasgupta, R; Gupta, AA; Hawkins, DS; Indelicato, DJ; Pappo, AS; Spunt, SL | 1 |
| Eckhoff, L; Knoop, A; Moeller, S; Nielsen, M | 1 |
| Alvarez, I; Arcari, A; Baldini, L; Chiappella, A; Di Rocco, A; Federico, M; Fragasso, A; Gobbi, PG; Ilariucci, F; Liberati, AM; Luminari, S; Mammi, C; Marcheselli, L; Mazza, P; Merli, F; Musso, M; Rossi, G; Salvi, F; Stelitano, C; Tucci, A | 1 |
| Chen, LP; Lin, SJ; Yu, MS | 1 |
| Blackwood, L; Grant, IA; Killick, DR; Marrington, AM | 1 |
| Rayson, D; Thompson, K; Younis, T | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P | 1 |
| Bustam, AZ; Ng, CH; Phua, CE; Saad, M; Taib, NA; Teh, YC; Yip, CH; Yusof, MM | 1 |
| Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S | 1 |
| Achard, JL; Charrier, S; Chollet, P; Cure, H; Dauplat, J; De Latour, M; Feillel, V; Ferriere, JP; Le Bouedec, G; Leduc, B; Van Praagh, I | 1 |
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Modollel, A; Muñiz, I; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S | 1 |
| Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, K; Lee, MH; Lee, SH; Lee, SI; Park, J; Park, JO; Park, K; Park, YS | 1 |
| Miles, D; Reichardt, P | 1 |
| Bonneterre, J; Catimel, G; Tubiana-Hulin, M | 1 |
| Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Costantini, M; Giannessi, P; Guarneri, V; Mammoliti, S; Moyano, A; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M | 1 |
| Abrial, CJ; Amat, S; Chollet, PJ; Curé, HD; Feillel, VA; Ferrière, JP; Kwiatkowski, FG; Lebouëdec, G; Mouret-Reynier, MA; Penault-Llorca, FM | 1 |
| Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D | 1 |
| He, PQ; Li, YF; Liu, GY; Shen, ZZ; Sheng, Y; Shi, JY; Su, FX; Yang, MT; Zou, Q | 1 |
| Bang, YJ; Ham, HS; Hong, YS; Im, SA; Im, YH; Kim, KW; Kim, SB; Kim, TY; Kim, WK; Lee, J; Lee, KE; Lee, KH; Lee, MA; Lee, MH; Lee, NS; Lee, SN; Park, HS; Park, YH; Seo, JH; Song, HS | 1 |
| Chamorey, E; Delwail, V; Fabbro, M; Foussard, C; Gressin, R; Harrousseau, JL; Lepeu, G; Maisonneuve, H; Peyrade, F; Richard, B; Rossi, JF; Thyss, A; Vilque, JP | 1 |
| Antimi, M; Barone, C; Botti, C; Calabresi, F; Carlini, P; Conti, F; Cortesi, E; Di Cosimo, S; Di Filippo, F; Di Lauro, L; Fabi, A; Ferretti, G; Giannarelli, D; Lopez, M; Marolla, P; Nisticò, C; Papaldo, P; Terzoli, E; Vici, P | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y | 1 |
| Koulentianos, E; Polyzos, A; Sfikakis, P; Tzianoumis, L | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| André, T; Bennamoun, M; Carola, E; Flesch, M; Gamelin, E; Louvet, C; Nguyen, S; Rebischung, C; Van Ongeval, J; Ychou, M | 1 |
| Choi, CW; Choi, IK; Choi, JG; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sul, HR; Sung, HJ | 1 |
| Bauernhofer, T; Dandachi, N; Holub, R; Samonigg, H; Schippinger, W | 1 |
| Botti, G; Comella, G; Comella, P; D'Aiuto, G; De Rosa, V; Di Bonito, M; Frasci, G; Iodice, G; Rubulotta, MR; Thomas, R | 1 |
| Fortner, BV; Houts, AC; Schwartzberg, LS | 1 |
| Ferretti, G; Papaldo, P | 1 |
| Antimi, M; Cognetti, F; Cortesi, E; Ferretti, G; Giannarelli, D; Lopez, M; Marolla, P; Papaldo, P; Terzoli, E | 1 |
| Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE | 1 |
| Bacon, P; Brugger, W; Clemens, M; Constenla, M; Easton, V; Fargeot, P; Mahlberg, R; Romieu, G; Schütte, M; Skacel, T | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Bu, Q; Cai, QQ; Gao, Y; Guan, ZZ; Huang, HQ; Jiang, WQ; Lin, XB; Pan, ZH; Wang, BF; Xia, ZJ; Xu, RH | 1 |
| Debled, M; Donamaria, C; Durand, M; Floquet, A; Houédé, N; Madranges, N; Mauriac, L | 1 |
| Adjei, AA; Aubry, MC; Delaune, R; Foster, NR; Kardinal, CG; Maurer, MJ; Nikcevich, DA; Northfelt, DW; Okuno, SH; Rowland, KM; Sloan, JA; Soori, GS | 1 |
| Hao, XM; Hui, R; Zhang, J; Zhang, M | 1 |
| Hansen, F; Skovsgaard, T; Stenbygaard, L | 1 |
| Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D | 1 |
| Bertini, M; Botto, B; Freilone, R; Gavarotti, P; Levis, A; Orlandi, E; Orsucci, L; Pini, M; Pizzuti, M; Vitolo, U | 1 |
| Bissett, D; Canney, PA; Evans, D; Habeshaw, T; Harnett, AN; Jodrell, D; Kaye, SB; Williams, M | 1 |
| Chevallier, B; Chollet, P; Fargeot, P; Fizames, C; Fumoleau, P; Genot, JY; Kerbrat, P; Merrouche, Y; Olivier, JP; Roche, H | 1 |
| Botti, C; Cercato, MC; Cognetti, F; Del Bianco, S; Ferraresi, V; Sacchi, I; Scinto, AF; Tonachella, R | 1 |
| Berkow, RL; Buchanan, GR; Cantor, AB; Castleberry, RP; Green, AA; Hayes, FA; Joshi, V; Leventhal, B; Mahoney, DH; Smith, EI | 1 |
| Aglietta, M; Carnino, F; Gavosto, F; Monzeglio, C; Pasquino, P; Stern, AC | 1 |
| Gurney, H; Harnett, P; Kefford, R; Stuart-Harris, R | 1 |
| Bengala, C; Conte, P; Giannessi, P; Michelotti, A; Romanini, A | 1 |
| Catimel, G; Chazard, M; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Soler-Michel, P; Spielmann, M | 1 |
| Baldini, E; Biadi, O; Conte, PF; DaPrato, M; Gentile, A; Giannessi, PG; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Diergarten, K; duBois, A; Hecker, D; Janicke, F; Konecny, G; Kuhnle, H; Lindner, C; Lisboa, BW; Luck, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Berdel, WE; Bron, DG; Cunningham, D; de Campos, E; De Greve, J; Howell, A; Seymour, AM; Steward, WP; Thatcher, N; Tueni, E | 1 |
| Campioni, N; Cognetti, F; Ferraresi, V; Giannarelli, D; Piarulli, L; Sacchi, I; Scinto, AF; Tonachella, R | 1 |
| Awada, A; Bartholomeus, S; Bruning, P; Paridaens, R; Piccart, MJ; Schornagel, JH; Thomas, J; Tomiak, E; Wildiers, J; Witteveen, PO | 1 |
| Baldini, E; Conte, PF; Da Prato, M; Gennari, A; Gentile, A; Michelotti, A; Salvadori, B; Salzano, E; Tibaldi, C | 1 |
| Bianco, AR; Curcio, C; D'Aprile, M; Gebbia, V; Gridelli, C; Palmeri, S; Pepe, R; Pistillucci, G; Rossi, A; Veltri, E | 1 |
| Bonneterre, J; Catimel, G; Dieras, V; Dumortier, A; Garet, F; Graffand, N; Guastalla, JP; Kayitalire, L; Pellae-Cosset, B; Pouillart, P; Spielmann, M; Tubiana-Hulin, M | 1 |
| Diergarten, K; du Bois, A; Hecker, D; Jänicke, F; Konecny, G; Kühnle, H; Lindner, C; Lisboa, BW; Lück, HJ; Meerpohl, HG; Thomssen, C; Untch, M | 1 |
| Baldini, E; Conte, P; da Prato, M; Evangelista, G; Giannessi, P; Lencioni, M; Meucci, C; Roncella, M; Spinelli, C; Tibaldi, C | 1 |
| Bishop, JF; Fenessy, A; Michael, M; Olver, IN; Toner, GC | 1 |
| Baldini, E; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Dell'Anna, R; Gennari, A; Gentile, A; Innocenti, F; Mariani, M; Michelotti, A; Salvadori, B; Tibaldi, C | 1 |
| Benavides, M; Cortés-Funes, H; García Conde, J; Hornedo, J; Lluch, A; López López, J; Sola, C; Solano, C | 1 |
| Adachi, I; Kanda, K; Murai, H; Ogita, M; Saeki, T; Sano, M; Sasaki, Y; Shimoyama, M; Tabei, T; Takashima, S; Watanabe, T | 1 |
| Fazeny, B; Fridrik, MA; Greil, R; Hausmaninger, H; Helm, W; Hudec, M; Klocker, J; Krieger, O; Neubauer, M; Oppitz, P; Pont, J; Radaszkiewicz, T; Simonitsch, I; Stöger, M | 1 |
| Dubbelman, R; Hiemstra, A; Lustig, V; Rodenhuis, S; ten Bokkel Huinink, WW | 1 |
| Ackland, S; Farrell, G; Gebski, V; Gurney, HP | 1 |
| Baldini, E; Bolognini, A; Chiavacci, F; Conte, P; Di Lieto, M; Fioretto, L; Ghezzi, P; Giallom-bardo, A; Taviani, R; Tibaldi, C | 1 |
| Arisawa, J; Hosoki, T; Inoue, Y; Masuzawa, M; Monden, M; Monden, T; Nakamura, H; Nakao, N; Ohi, H; Ohsaki, Y; Sakon, M; Seki, K; Shimizu, T; Todo, A; Tomono, N; Yayoi, E | 1 |
| Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G | 1 |
| Carmichael, J; Harris, AL; Mitchell, K; Philip, PA; Rea, D; Talbot, DC | 1 |
| Fattorossi, A; Greggi, S; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Salerno, G; Scambia, G | 1 |
| Bosquée, L; Canon, JL; Humblet, Y; Rosier, JF; van de Velde, H; Weynants, P | 1 |
| Bekradda, M; Bensmaïne, MA; Brain, E; Cvitkovic, E; Di Palma, M; Garrino, C; Goupil, A; Misset, JL; Soulié, P | 1 |
| Einhorn, LE; Loesch, D; Miller, DK; Munshi, N; Sledge, GW | 1 |
| Comte-Bardonnet, M; Daurès, JP; Khial, F; Marcillac, I; Oliver, P; Pujol, JL; Quantin, X; Rivière, A | 1 |
| Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A | 1 |
| Boyer, M; Gurney, H; Lewis, C; McKendrick, J; Millward, M; Richardson, G; Rischin, D; Smith, J; Toner, G | 1 |
| Carmichael, J; Howells, A; Jones, A; Lind, M; Poole, C; Stuart, N; White, J | 1 |
| Bauer, J; Borner, M; Crivellari, D; D'Incalci, M; Goldhirsch, A; Graffeo, R; Hess, D; Lombardi, D; Martinelli, G; Nolè, F; Pagani, O; Sessa, C; Thürlimann, B; Zucchetti, M | 1 |
| Angus, B; Carey, PJ; Finney, RD; Galloway, MJ; Goff, DK; Haynes, A; Jackson, GH; Lennard, AL; Leonard, RC; McQuaker, IG; Proctor, SJ; Russell, N; Taylor, PR; Windebank, K | 1 |
| Gregory, RK; Johnston, SR; Miles, D; Smith, IE | 1 |
| Anchisi, S; Anguenot, JL; Bonnefoi, H; Hügli, A; Mermillod, B; Sappino, AP; Schafer, P | 1 |
| Baldelli, AM; Barni, S; Casaretti, R; Cascinu, S; Catalano, G; Catalano, V; Comella, G; Frontini, L; Graziano, F; Labianca, R | 1 |
| Bertuzzi, A; Capri, G; Cresta, S; Giani, A; Gianni, L; Grasselli, G; Locatelli, A; Materazzo, C; Perotti, A; Spreafico, C; Tarenzi, E; Valagussa, P; Viganò, L | 1 |
| Abela, K; Aravantinos, G; Bafaloukos, D; Briassoulis, E; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, E; Kalofonos, HP; Kosmidis, P; Moulopoulos, LA; Papadimitriou, C; Papakostas, P; Pavlidis, N; Razis, E; Skarlos, D | 1 |
| Abrahamova, J; Kocak, I; Kroslakova, D; Kubala, E; Machova, D; Malec, V; Pavlikova, E; Pavlikova, I; Prausova, J; Simova, E; Sirakova, I; Tuma, P; Van Praagh, I; Wagnerova, M | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Palamidas, P; Raptis, A | 1 |
| Aloe, A; Carlini, P; Cognetti, F; De Marco, S; Fabi, A; Magnani, E; Nardi, M; Pacetti, U; Ruggeri, EM | 1 |
| Cottu, PH; Cuvier, C; de Roquancourt, A; Espie, M; Extra, JM; Laurence, V; Lerebours, F; Makke, J; Marolleau, JP; Marty, M; Mayeur, D; Miclea, JM | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
| Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Botti, G; D'Aiuto, G; De Maio, E; de Matteis, A; Labonia, V; Landi, G; Mastro, AA; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Angiolini, C; Baldini, A; Bergaglio, M; Canavese, G; Del Mastro, L; Garrone, O; Lambiase, A; Merlano, M; Rosso, R; Tolino, G; Venturini, M | 1 |
| Bracarda, S; Crinò, L; Darwish, S; de Angelis, V; de Marinis, F; Latini, P; Maranzano, E; Meacci, L; Minotti, V; Panizza, BM; Piro, F; Tonato, M | 1 |
| Dimopoulos, MA; Economopoulos, T; Fountzilas, G; Mellou, S; Nicolaides, C; Papadopoulos, A; Papageogriou, E; Papasavvas, P; Pavlidis, N; Samantas, E; Tsatalas, C | 1 |
| Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Levine, MN; Perrault, D; Pritchard, K; Skillings, J; Warr, D | 1 |
| Guaraldi, M; Martoni, A; Melotti, B; Pannuti, F | 1 |
| Burkes, RL; Goss, PE; Paul, KE; Shepherd, FA | 1 |
| Bastit, P; Chevallier, B; Fachini, T; Kerbrat, P; Montcuquet, P; Nguyen Bui, B; Vo Van, ML | 1 |
| Blackledge, GR; Child, JA; Ellis, IO; Fletcher, J; Jones, EL; Kavanagh, JA; Kelly, KA; O'Brien, CJ; Perren, TJ; Stuart, NS | 1 |
2 review(s) available for epirubicin and Neutropenia
| Article | Year |
|---|---|
Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Nervous System; Neutropenia; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2019 |
Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Epirubicin; Fever; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Taxoids | 2012 |
101 trial(s) available for epirubicin and Neutropenia
| Article | Year |
|---|---|
Results of NC-6300 (Nanoparticle Epirubicin) in an Expansion Cohort of Patients with Angiosarcoma.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Hemangiosarcoma; Humans; Micelles; Nanoparticles; Neutropenia; Polymers; Proteins; Thrombocytopenia | 2022 |
Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
Topics: Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2023 |
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Everolimus; Exanthema; Female; Humans; Mastectomy, Segmental; Middle Aged; Mucositis; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Sirolimus; Thrombocytopenia; Treatment Outcome | 2013 |
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Deoxycytidine; Epirubicin; Female; Gastrointestinal Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Proteasome Inhibitors; Pyrazines | 2014 |
The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Leukocyte Count; Middle Aged; Neutropenia; Neutrophils; Recombinant Proteins | 2013 |
A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Diarrhea; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplastic Cells, Circulating; Neutropenia; Receptor, ErbB-2; Survival Rate; Taxoids; Thrombocytopenia; Young Adult | 2013 |
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Treatment Outcome | 2014 |
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Induction Chemotherapy; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotoxicity; Cisplatin; Cyclophosphamide; Diarrhea; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Receptor, ErbB-2; Stroke Volume; Taxoids; Trastuzumab | 2016 |
Population-based phase I trial of irinotecan and epirubicin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Topoisomerase I Inhibitors | 2008 |
[Phase II study of docetaxel plus epirubicin versus docetaxel plus cisplatin as first-line chemotherapy for advanced breast cancer].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies; Remission Induction; Taxoids; Young Adult | 2008 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Patient Selection; Pilot Projects; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Treatment Outcome | 2009 |
Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Treatment Outcome | 2009 |
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Early Diagnosis; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lethargy; Leukopenia; Middle Aged; Neutropenia; Proportional Hazards Models; Receptors, Estrogen; Taxoids; Treatment Outcome; United Kingdom | 2009 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Fluorouracil; Humans; Lymph Nodes; Middle Aged; Mucositis; Neutropenia; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Taxoids | 2010 |
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Palliative Care; Retrospective Studies; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2009 |
[Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Ciprofloxacin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hospitals, General; Humans; Japan; Middle Aged; Neutropenia; Taxoids | 2009 |
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids | 2010 |
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Time Factors; Young Adult | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden | 2011 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINT
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multivariate Analysis; Neutropenia; Prednisone; Proportional Hazards Models; Prospective Studies; Rituximab; Treatment Outcome; Vincristine | 2012 |
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Premenopause; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vomiting | 2012 |
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2003 |
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Palliative Care; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left | 2004 |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Quality of Life | 2004 |
Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Retrospective Studies; Treatment Outcome | 2004 |
[Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 2005 |
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Pyruvaldehyde; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Middle Aged; Neutropenia; Recombinant Proteins | 2005 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granisetron; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neutropenia; Vomiting, Anticipatory | 2005 |
Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second and first line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Diarrhea; Drug Administration Schedule; Epirubicin; Fatigue; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2006 |
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Opportunistic Infections; Polyethylene Glycols; Premedication; Recombinant Proteins; Treatment Outcome | 2007 |
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quality of Life; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 2008 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Vomiting | 2007 |
Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prospective Studies | 1995 |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Neutropenia | 1995 |
P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Neutropenia; Prednisone; Prognosis; Remission Induction; Survival Rate; Vinblastine | 1994 |
Phase I study of accelerated FEC with granulocyte colony-stimulating factor (Lenograstim) support.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Menopause; Middle Aged; Neoplasm Staging; Neutropenia; Postmenopause; Premenopause; Recombinant Proteins | 1995 |
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Infections; Lenograstim; Middle Aged; Neutropenia; Pharmaceutical Vehicles; Recombinant Proteins; Thrombocytopenia | 1995 |
Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome | 1994 |
Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Infant; Male; Neuroblastoma; Neutropenia; Organoplatinum Compounds; Remission Induction | 1994 |
Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Methotrexate; Middle Aged; Neutropenia; Thrombocytopenia | 1993 |
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Hemoglobins; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Middle Aged; Neutropenia; Salvage Therapy; Time Factors; Vincristine | 1995 |
Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Neutropenia; Sarcoma; Treatment Outcome | 1996 |
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fever; Heart Diseases; Humans; Middle Aged; Neutropenia; Paclitaxel | 1996 |
Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Remission Induction | 1996 |
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Combination; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Leukocyte Count; Lymphoma; Male; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Single-Blind Method | 1995 |
Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Recombinant Proteins; Remission Induction | 1995 |
An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Europe; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Pilot Projects; Recombinant Proteins; Remission Induction | 1995 |
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Tolerance; Epirubicin; Feasibility Studies; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart; Heart Failure; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Recombinant Proteins; Remission Induction; Stroke Volume; Ventricular Function, Left | 1996 |
Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Small Cell; Cause of Death; Dose-Response Relationship, Drug; Drug Tolerance; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sepsis; Thrombocytopenia | 1996 |
Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; Cyclophosphamide; Epirubicin; Female; France; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Injections, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel | 1997 |
Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leucovorin; Leukocyte Count; Methotrexate; Middle Aged; Neutropenia; Recombinant Proteins; Survival Rate; Vincristine | 1997 |
Phase I dose intensification study of 2-weekly epirubicin with GM-CSF in advanced cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Prospective Studies | 1997 |
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Heart Diseases; Humans; Least-Squares Analysis; Middle Aged; Neutropenia; Paclitaxel; Prospective Studies; Stroke Volume; Survival Analysis; Treatment Outcome | 1997 |
[Multicentric prospective, randomized study of the role of filgrastim (G-CSF) after transplant of hematopoietic progenitor cells mobilized with G-CSF in patients with cancer of the breast].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neutropenia; Prospective Studies; Recombinant Proteins; Thiotepa | 1997 |
A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neutropenia; Prospective Studies; Receptors, Estrogen; Recombinant Proteins; Survival Rate; Thrombocytopenia | 1997 |
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Epirubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lymphocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Neutropenia; Prednisolone; Recombinant Proteins; Vincristine | 1997 |
Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1997 |
Epirubicin/vinorelbine as first line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 1998 |
[Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Epirubicin; Fever; Hepatic Artery; Humans; Injections, Intra-Arterial; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1998 |
A pilot study of increasing dose intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using recombinant granulocyte colony-stimulating factor.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Prospective Studies; Recombinant Proteins; Treatment Outcome | 1999 |
Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomiz
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Combined Modality Therapy; Drug Synergism; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Statistics, Nonparametric; Treatment Outcome | 1999 |
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clini
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Epirubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Nervous System Neoplasms; Neutropenia; Recurrence; Survival Rate; Thoracic Neoplasms; Thrombocytopenia; Treatment Outcome | 1999 |
Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Dactinomycin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Epirubicin; Etoposide; Germinoma; Humans; Ifosfamide; Male; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Testicular Neoplasms; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Treatment Outcome; Ventricular Function, Left | 2000 |
Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Treatment Outcome | 2000 |
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2000 |
A phase II trial of paclitaxel and epirubicin in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
A multicentre phase II pilot study of epirubicin and Taxol (paclitaxel) in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Heart Function Tests; Humans; Middle Aged; Neutropenia; Paclitaxel; Treatment Outcome | 2000 |
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Neutropenia; Peripheral Blood Stem Cell Transplantation; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Thrombocytopenia; Transplantation Conditioning; Treatment Outcome | 2000 |
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Humans; Infusions, Intravenous; Leucovorin; Middle Aged; Neutropenia; Tegafur; Uracil | 2000 |
Infusional ECarboF in patients with advanced breast cancer: a very active and well-tolerated out-patient regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia | 2000 |
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Fatigue; Female; Fluorouracil; Glutathione; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leucovorin; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2001 |
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Epirubicin; Female; Humans; Myocardium; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2001 |
Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Topotecan | 2001 |
Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2001 |
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Injections, Subcutaneous; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival; Treatment Outcome; Vincristine | 2002 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Neutropenia; Prednisolone; Prednisone; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2002 |
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neutropenia; Pilot Projects | 1992 |
Activity of high-dose epirubicin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Evaluation; Epirubicin; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Stroke Volume | 1991 |
A phase II study of 4'-epirubicin in the treatment of poor-risk Kaposi's sarcoma and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Drug Evaluation; Epirubicin; Humans; Male; Middle Aged; Neutropenia; Ontario; Prospective Studies; Remission Induction; Sarcoma, Kaposi; Survival Rate | 1991 |
41 other study(ies) available for epirubicin and Neutropenia
| Article | Year |
|---|---|
[Comparison of Adverse Events during EC or TC Therapy for Breast Cancer at the Kakogawa Central City Hospital].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hospitals, Urban; Humans; Neutropenia; Treatment Outcome | 2021 |
Search for nutritional and inflammatory marker ratios to predict neutropenia in FEC therapy for breast cancer: A retrospective observational study.
Topics: Biomarkers; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neutropenia; Prognosis; Retrospective Studies | 2022 |
Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Genital Neoplasms, Male; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Paget Disease, Extramammary; Prognosis; Progression-Free Survival; Retrospective Studies; Scrotum; Severity of Illness Index; Thrombocytopenia; Vulvar Neoplasms | 2019 |
A Retrospective Study of Multi-agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High-grade T-cell Lymphoma (2011-2017).
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dog Diseases; Dogs; Epirubicin; Female; Lomustine; Lymphoma, T-Cell; Male; Neutropenia; Prednisolone; Retrospective Studies; United Kingdom; Vincristine | 2019 |
Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diarrhea; Docetaxel; Drug Eruptions; Epirubicin; Feasibility Studies; Female; Humans; Middle Aged; Myalgia; Neutropenia; Pilot Projects; Taxoids | 2013 |
Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutropenia; Neutrophils; Prospective Studies | 2014 |
Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Epirubicin; Female; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Retrospective Studies; Treatment Outcome | 2015 |
[Neoadjuvant chemotherapy using epirubicin, cyclophosphamide and fluorouracil: neutropenia and elevation of transaminase, and their management].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Neoadjuvant Therapy; Neutropenia; Retrospective Studies; Transaminases | 2015 |
[Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Liposomes; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2015 |
Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Incidence; Japan; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2017 |
[Influence of Next-Day Administration of Pegfilgrastim after FEC100 Chemotherapy in Japanese with Breast Cancer on Neutrophil Count].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies | 2017 |
Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematologic Tests; Humans; Immune Tolerance; Laboratories, Hospital; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Time Factors; Young Adult | 2009 |
Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Treatment Outcome | 2010 |
Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer.
Topics: Adult; Aged; Anthracyclines; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Prognosis; Taxoids; Treatment Outcome | 2010 |
Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fever; Humans; Maximum Tolerated Dose; Medical Audit; Middle Aged; Neutropenia; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fever; Fluorouracil; Genetic Association Studies; Humans; Middle Aged; Mutation, Missense; Neutropenia; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-mdm2; Sequence Analysis, DNA; Tumor Suppressor Protein p53 | 2012 |
Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Topics: Adolescent; Age Factors; Anemia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Female; Humans; Ifosfamide; Incidence; Male; Mesna; Neutropenia; Rhabdomyosarcoma; Sex Characteristics; Survival Rate; Thrombocytopenia; Vincristine; Young Adult | 2012 |
TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Denmark; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Retrospective Studies; Taxoids | 2011 |
Prognostic value of platelet count in diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Multivariate Analysis; Neutropenia; Platelet Count; Prednisolone; Prognosis; Retrospective Studies; Rituximab; Thrombocytopenia; Treatment Outcome; Vincristine; Young Adult | 2012 |
Toxicity associated with epirubicin treatments in a large case series of dogs.
Topics: Animals; Antibiotics, Antineoplastic; Dog Diseases; Dogs; Epirubicin; Female; Fever; Gastrointestinal Diseases; Male; Neoplasms; Neutropenia; Retrospective Studies | 2012 |
Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cause of Death; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Female; Fever; Fluorouracil; Humans; Malaysia; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Taxoids | 2012 |
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lenograstim; Male; Middle Aged; Neutropenia; Recombinant Proteins; Sarcoma; Soft Tissue Neoplasms; Young Adult | 2013 |
Efficacy of a primary chemotherapy regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Epirubicin; Female; Humans; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Setting the record straight: activity of gemcitabine monotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Epirubicin; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neutropenia; Survival Rate; Venous Thrombosis | 2005 |
Increased dosage of epirubicin and mitomycin-C for the treatment of metastatic adenocarcinoma of unknown primary site.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Biopsy; Dose-Response Relationship, Drug; Epirubicin; Humans; Leukopenia; Male; Mitomycin; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 1989 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Cells; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neutropenia; Prednisone; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2006 |
Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lenograstim; Middle Aged; Neutropenia; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2006 |
A prospective investigation of chemotherapy-induced neutropenia and quality of life.
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Cisplatin; Cyclophosphamide; Depression; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Neutropenia; Prednisone; Prospective Studies; Psychiatric Status Rating Scales; Psychometrics; Quality of Life; Regression Analysis; Severity of Illness Index; Sickness Impact Profile; Taxoids; Treatment Outcome; United States; Vincristine | 2006 |
Can the addition of prophylactic filgrastim be considered cost effective in early breast cancer patients treated with epirubicin and cyclophosphamide?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cyclophosphamide; Epirubicin; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Neutropenia; Recombinant Proteins | 2006 |
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocytosis; Neutropenia; Recombinant Proteins | 2006 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
[CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Vincristine | 2007 |
Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Retrospective Studies; Taxoids | 2007 |
Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neutropenia; Paclitaxel; Ventricular Function | 1996 |
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Antipyrine; Bile Acids and Salts; Body Surface Area; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Liver Function Tests; Male; Middle Aged; Neutropenia | 1998 |
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Thrombocytopenia | 1999 |
Phase II study of epirubicin in advanced soft tissue sarcoma.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Drug Screening Assays, Antitumor; Epirubicin; Female; Humans; Male; Middle Aged; Neutropenia; Sarcoma; Soft Tissue Neoplasms | 1990 |
A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Neutropenia; Procarbazine; Vincristine | 1988 |